Sign In
Buy ONCY
$0.94
+0.0237 (+2.58%)
At Close: Jun 23, 2026
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday
01:16am, Friday, 27'th Feb 2026
Oncolytics Biotech (NASDAQ: ONCY - Get Free Report) is expected to release its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect Oncolytics Biotech to post earnings of ($0.
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
09:00am, Tuesday, 24'th Feb 2026
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate ma
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
11:17am, Tuesday, 17'th Feb 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
Oncolytics Biotech (NASDAQ:ONCY) Trading 1.3% Higher – Here’s Why
04:34am, Thursday, 12'th Feb 2026
Oncolytics Biotech Inc. (NASDAQ: ONCY - Get Free Report)'s share price rose 1.3% on Wednesday. The company traded as high as $0.86 and last traded at $0.8535. Approximately 1,728,312 shares were trade
$207B Market Shift: The Race for Fast Track Approval in Oncology
09:35am, Thursday, 05'th Feb 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
08:50am, Wednesday, 04'th Feb 2026
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
10:36am, Friday, 30'th Jan 2026
/PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
04:01pm, Thursday, 15'th Jan 2026
SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today annou
Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
11:16am, Thursday, 15'th Jan 2026
Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
10:52am, Wednesday, 14'th Jan 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no app
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
09:00am, Friday, 09'th Jan 2026
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provi
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
09:00am, Thursday, 08'th Jan 2026
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the expansio
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced clinical and
